Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Presentation

DES vs DCB Revascularization in Patients With Femoropopliteal Arterial Disease

February 11, 2019

Presentation

12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment

May 08, 2018

Presentation

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Presenter: Kenneth Rosenfield

June 25, 2015

Presentation CCVVC 2015

Covered Stents in Femoropopliteal Disease

Presenter: Subhash Banerjee

June 18, 2015

Presentation

Insights from Real-World Femoropopliteal Drug-Coated Balloon (DCB) Treatment: 1-Year Results From IN_PACT Global Clinical Study

Presenter: G.Tepe

February 04, 2015

Presentation

DEBs for Femoropopliteal Lesions Show Better Performance in De Novo Stenosis Than Restenosis

Presenter: Monika Herten

October 16, 2014

Presentation EuroPCR 2014

Post‐Market Surveillance Study of Paclitaxel‐Eluting Nitinol Stents for Treating FemoropoplitealArtery Disease in Japan: 12‐Month Results

Presenter: Hiroyoshi Yokoi

May 21, 2014

Presentation TCT 2013

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

Presenter: Kenneth Rosenfield

October 30, 2013

Presentation

Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions

Presenter: Michael D. Dake

April 10, 2013

Presentation

Two-Year Results of Paclitaxel-Eluting Balloons (PEB) for Femoropopliteal Artery Disease

Presenter: Antonio Micari

April 03, 2013

Presentation

Treatment of Femoropopliteal In-Stent Restenosis with Paclitaxel-Eluting Stents

Presenter: T. Zeller

April 03, 2013

Presentation

Paclitaxel-Coated Balloons Reduce Restenosis After Femoropopliteal Angioplasty

Presenter: Michael Werk

December 06, 2012

Presentation TCT 2012

TCT-585: Six-Month Results of the BIOLUX P-I First-in-Man Study Comparing a Paclitaxel-Releasing Balloon Catheter vs. an Uncoated Balloon Catheter in Femoropopliteal Lesions

Presenter: Dierk Scheinert

October 23, 2012

Presentation

Paclitaxel-Coated vs. Uncoated Balloon Angioplasty Reduces TLR in Femoropopliteal Disease

Presenter: S. Cassese

August 06, 2012

Presentation TCTAP 2012

Drug-Eluting Balloon or Stent In Femoropopliteal Lesions: How Far Are We?

Presenter: Mark W. Burket

April 25, 2012

Presentation TCT 2012

The Pacifier Trial. A Randomized Multicenter Trial Evaluating Prevention of Restenosis with Paclitaxel-Coated PTA Balloon Catheters in Stenosis or Occlusion of Femoropopliteal...

Presenter: Michael Werk, Thomas Albrecht, Dirk R. Meyer, Heiner Stiepani, Beatrix Schnorr, Enrique Lopez H?nninen

January 03, 2012

Advertisement

DES vs DCB Revascularization in Patients With Femoropopliteal Arterial Disease

12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment

Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease

Covered Stents in Femoropopliteal Disease

Insights from Real-World Femoropopliteal Drug-Coated Balloon (DCB) Treatment: 1-Year Results From IN_PACT Global Clinical Study

DEBs for Femoropopliteal Lesions Show Better Performance in De Novo Stenosis Than Restenosis

Post‐Market Surveillance Study of Paclitaxel‐Eluting Nitinol Stents for Treating FemoropoplitealArtery Disease in Japan: 12‐Month Results

LEVANT 2: A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon vs. Standard Balloon Angioplasty in Diseased Femoropopliteal Arteries

Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions

Two-Year Results of Paclitaxel-Eluting Balloons (PEB) for Femoropopliteal Artery Disease

Treatment of Femoropopliteal In-Stent Restenosis with Paclitaxel-Eluting Stents

Paclitaxel-Coated Balloons Reduce Restenosis After Femoropopliteal Angioplasty

TCT-585: Six-Month Results of the BIOLUX P-I First-in-Man Study Comparing a Paclitaxel-Releasing Balloon Catheter vs. an Uncoated Balloon Catheter in Femoropopliteal Lesions

Paclitaxel-Coated vs. Uncoated Balloon Angioplasty Reduces TLR in Femoropopliteal Disease

Drug-Eluting Balloon or Stent In Femoropopliteal Lesions: How Far Are We?

The Pacifier Trial. A Randomized Multicenter Trial Evaluating Prevention of Restenosis with Paclitaxel-Coated PTA Balloon Catheters in Stenosis or Occlusion of Femoropopliteal...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content